Pfizer Inc. (NYSE:PFE) announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults. RSV affects 33 million children globally and leads to approximately 120,000 childhood deaths every year. (1) In the United States approximately 177,000 older adults are hospitalized annually because of RSV.(2) The highest risk of severe outcome from RSV occurs in the first months of life.
Read more: http://www.worldpharmanews.com/pfizer/4414-pfizer-begins-a-phase-1-2-study-to-evaluate-respiratory-syncytial-virus-rsv-vaccine